Moreover, this is of particular interest since ongoing trials are currently testing efficacy and safety of anti-C5 antibodies (clinical trial: NCT04564339) and C5a receptor (C5aR) antagonists (clinical trial: NCT02151409) in patients with lupus nephritis. The gene discussed is C5; the disease is lupus nephritis.